AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: Homologous erythrocytes as a delivery system for preferential immunization with putative protective antigens

Feline immunodeficiency virus (FIV) is a useful model for testing of criteria for AIDS vaccine development, In the protocol we adopted, we used a primary isolate of FIV as a source of antigen and, for challenge, plasma from cats infected with the homologous virus never passaged in vitro. Cat erythrocytes (RBC) were coated with the surface components of freshly harvested and purified PIV by means of biotin-avidin-biotin bridges and used to immunize specific-pathogen-free cats (four doses at monthly intervals; total amount of FIV antigen administered per cat, approximately 14 mu g). Immunized cats developed moderate levels of antibodies directed mainly to surface components of the virion and clearly evident Lymphoproliferative responses. Four months after the last dose of immunogen, FIV-immunized cats and control cats immunized with bovine serum albumin-coated RBC were challenged, Judged from the results of the subsequent 12-month follow-up, FIV-immunized eats exhibited at least some degree of protection, However, following rechallenge, most of the FIV-immunized animals became virus positive in spite of a booster immunogen dose given 2 months before the second challenge.